Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 10.67 as of 2026-10-06T15:57:04.725Z.
Consensus retrieved: 2026-10-06T13:36:26.962Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:57:04.725Z.
Quote observation: 2026-10-06T15:55:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 295890ca45b9fb7c845dc9b7cfc12ce3e82df22f7cd737cbd4420fef5fb5231a
Forward PE Ratio (10.67) = Dated Quote Price ($26.52) / Consensus Forward EPS ($2.49)
FORWARD PE RATIO
10.67
SECTOR MEDIAN · HEALTHCARE
19.77
median of 173 covered companies
CURRENT VS SECTOR MEDIAN
-46.03%
vs the sector median at left
Liquidia Corporation
Market Cap
$2.36B
Forward PE Ratio
10.67
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Liquidia Corporation (LQDA) | $2.36B | 10.67 |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.37B | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.39B | 12.95 |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 82.57 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 10.13 |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.41B | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.30B | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.46B | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.15B | N/A |
Trailing P/E
19.4
reported TTM EPS
Forward P/E
10.7
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.49 implies +81.8% EPS growth vs the reported trailing $1.37.
At the dated quote price of $26.52, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.49 | $1.77 – $3.65 | 5 | 10.7x |
| 2027-12-31 | $2.34 | $0.89 – $3.96 | 5 | 11.3x |
| 2028-12-31 | $3.16 | $1.71 – $4.52 | 5 | 8.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
